PhaseBio Pharmaceuticals
Malvern
About PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods. PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013. PhaseBio is based in Malvern, Pennsylvania.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $324.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2021)
- Ticker: nasdaq:PHAS
- Website: phasebio.com
- Phone: 16109816520
Industries & Categories
Biotechnology, Medical, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/phasebio-pharmaceuticals-86515 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.